The purpose of the study was to characterize the immune status in 88 patients (64 women and 24 men) with thyroid diseases and in 36 healthy blood donors as control group. The clinical material consisted of 37 patients with nontoxic nodular goitre, 10 patients with thyroiditis, 27 patients with thyroid adenoma and 14 patients with thyroid carcinoma. The studied parameters included serum neopterin,interleukin-6 (IL-6), also anti-thyroglobulin autoantibodies (ATG) and anti-thyroid microsomal autoantibodies (MAB). The aim of the study was to investigate whether serum neopterin, IL-6, ATG and MAE have any value in distinction between non-toxic nodular goitre, thyroiditis, thyroid adenoma and thyroid carcinoma. 36.4% patients with thyroid carcinoma, 16.7% patients with nontoxic nodular goitre and 9.1 % patients with thyroid adenoma had neopterin levels higher than 10 nmol/1. In patients and in the control group the mean serum levels of neopterin were in normal range. The highest mean level of neopterin was found in patients with thyroid carcinoma (7.14± 5.95 nmol/l). The difference was statistically significant in comparison to the control (p:<::: 0.001) and patients with thyroiditis and thyroid adenoma (p < 0.05). The significantly higher levels of IL-6 were in all patients in comparison to the control (p < 0.0001). Autoantibodies ATG \\-ere detected in serum of 45 patients (51.1 %) and autoantibodies MAE were in serum of 34 patients (38.6 % ). Mean levels of these autoantibodies in patients were statistically significantly higher than in the control ' p < 0.05). In patients with ATG and/or MAE mean level of neopterin was significarltly higher than in patients WitI-lOut these autoantibodies (p < 0.05). This study has shown that neopterin represents an additional parameter with potential interest in clinical diagnosis of thyroid diseases.
Introduction
The lymphocytes and monocytes playa key role in host defense through their effector and accessory cell tt1l1ction. Upon stimulation they release high levels of neopterin and cytokines such as interleukin-6 ( 11). Neopterin is a low molecular weight pteridine compound converted from guanosine triphosphate (GTP). It is released by activated human monocytes/ macrophages upon stimulation with interferon-y produced by activated T-Iymphocytes (6, 12) . The serum levels of neopterin can thereiexe be seen as an indication of the activation state of the T-IymphoLJrte/macrophage axis (20, 22) . In individuals with normal renal function raised neoptcrin levels are generally associated with increased cellular immune activation. An increased neopterin level is a sensitive indicator of conditions involving activation of cellular immunity, but is not specific for a certain disease. (13) . Neopterin concentrations correlate with the extent and activity of viral infections, malignancies and autoimmune diseases (9 ) .
Interleukin-6 (IL-6) is a multifunctional smallpeptide molecule that is produced by a variety of cells including T-Iymphocytes, monocytes and macrophages. Biologic properties attributed to IL-6 include its ability to induce B-cell differentiation. It plays a central role in host defense mechanisms and acute-phase reaction, including regulation of inflammatory and immune responses. Elevated IL-6 levels have been reported to be associated with a variety of diseases, including autoimmune diseases (14) .
Thyroid diseases are common in family practice. Although thyroid disease is often suspected on the basis of the history and the physical examination, laboratory diagnosis is often difficult. The present study was wldertaken in order to estimate serum neopterin, interleukin-6, also anti-thyroglobulin autoantibodies (ATG) and anti-thyroid microsomal autoantibodies (MAB) levels in patients with thyroid diseases (3) . We wanted to investigate whether measurements of these m arkers could distinguish between the thyroid nontoxic goitre, thyroiditis, thyroid adenoma and dlyroid carcinoma. We wondered whedler neopterin measurement could be used as marker of disease activity in thyroid diseases.
Materials and Methods

Patients with thyroid diseases
We studied 88 hypothyroid patients (64 women and 24 men). The mean age was 42.3 years (range 26-55). The clinical material consisted of 37 patients (3 1 women and 6 men) with nontoxic nodular goitre, 10 patients (5 women and 5 men ) with thyroiditis, 27 patients (21 women and 6 men) with dlyroid adenoma and 14 patients (7 women and 7 men) with dl)Toid carcinoma. The diagnosis was based on clinical criteria and confirmed by appopriate diagnostic tests. All samples were drawn on adminission bet"(xe surgery.
Control group
36 healdlY blood donors (20 women and 16 men) at mean age 39.6 years, in the range from 24 to 50 years, were normal control for the thyroid patients. All were biochemically euthyroid and their senlfl1 was negative for d-lyroid autoantibodies.
Blood from patients and control was collected by venipuncture. Sera were stored at -7a'C and processed together. All patients were asked for informed consent prior to entry into the study. The study was approved by the local edlical committee. The neopterin concentration in serum was measured by N eopterin ELISA kit (Merck Diagnostica, Darmstadt, Germany). Neopterin concentrations::; to 10 nmoljl were considered as normal. Interleukin-6 (IL-6) in serum was m easured by ELISA (R&D Systems, Biermann, Germany). Anti-thyroglobulin autoantibodies (ATG) and anti-thyroid microsomal autoantibodies (MAB) were determined by comercially available ELISA kits. The methods used for measuring neopterin, interleukin-6 and autoantibodies ATG and MAB were performed according to instruction manuals of the manufacturers. Serum levels of these parameters were measured by the plate reader ELx800 Bio~ek Instruments Inc. USA.
Statistical Analyses
The Mann-Whitney U and Student-t tests were w;ed for statistical evaluation. The differences were considered as statistically significant for p::; 0.05.
Results
Serum neopterin and interleukin 6 levels in normal controls and in all groups of patients with thyroid diseases are presented in Table 1 . In all patients and in normal controls llie mean serum levels of neopterin were within the normal range. The highest mean level of neopterin was fOlmd in patients with thyroid carcinoma. Significantly higher levels of neopterin were found in dlyroid carcinoma compared to the control group (p < 0 .001 ) and to patients willi thyroiditis and to thyroid adenoma (p < 0 .05) . However, there was no significant difference in neopterin levels between thyroid carcinoma and thyroid nontoxic nodular goitre. The percentage o f patients with levels of neopterin higher than 10 nmoljl was different in patients willi thyroid disease (Figure 1) . Serum interleukin-6 (IL-6) levels in patients and normal control are presented in Table 1 . The highest mean level of IL-6 was fC>Llnd in thyroid adenoma. Significantly higher mean levels of IL-6 were in all patients with dlyroid diseases compared to normal controls (p < 0.0001 ).
Anti-thyroglobulin autoantibodies (ATG) were detected in serum of 16 patients (43.2%) with nontoxic nodular goitre, 9 patients (90.0 %) with thyroiditis, 11 patients with thyroid adenoma (40.4%) and in 9 patients with thyroid carcinoma (64.2%) . .wti-thyroid microsomal autoantibodies (MAB) were detected in serum of 11 patients with nontoxic nodular goitre (29.7%), 7 patients with thyroiditis (70.0%), 6 patients with thyroid adenoma (22.2%) and in 10 ~,atients with thyroid carcinoma (71.4%). Mean lcv-: ]s of these autoantibodies in patients were signiflcantly higher than in normal control (p < 0.05 ) . In patients with autoantibodies ATG and/or MAE mean level of neopterin was significantly higher than in patients without these autoantibodies (p < 0.05 ), but we didnt flnd a significant correlation between the level of neopterin and the levels of ATG and MAE. Autoantibodies ATG and MAB were not detected in normal control.
Discussion
Although thyroid disease is often suspected on the basis of the history and the physical examination, clinical diagnosis is often difficult (16) . Laboratory testing is necessary to confirm the diagnosis and monitor response to treatment (5, 15, 17) . In thyroid diseases migration of mononuclear cells is controlled by inflammatory cytokines and adhesion molecules. B cells and extracellular matrix, resulting in the proliferation of T cells, produce cytokines and autoantibodies (2, 7, 18) .
The purpose of our study was to characterize the immune function in patients with thyroid diseases as well as nontoxic nodular goitre, thyroiditis, thyroid adenoma and thyroid carcinoma. The studied parameters included serum neopterin, IL-6 also anti-thyroglobulin (ATG) and anti-thyroid microsomal (MAE) autoantibodies.
The present study shows that in patients with all thyroid diseases the mean serum levels of neopterin were within the normal range. The highest mean level of neopterin was found in patients w ith thyroid carcinoma. Significantly higher levels of neopterin were observed in thyroiditis and thyroid adenoma compared with the control group. Higher values than 10 nmoljl of neopterin were found in thyroid carcinoma, thyroid adenoma and in nontoxic nodular goitre.
Neopterin is recognized as a biochemical marker for activation of cell-mediated immlmity (8) . In healthy people monocytes are not activated, since neopterin, a specific marker of monocyte activation, and other cytokines, such as interleukin-6, can be detected only at low levels or not at all ( 11 ) . Numerous clinical studies which were conducted by a number of research groups in several countries have shown that high neopterin levels are observed in clinical settings recognized or supposed to involve activated cell-mediated immunity (4 ) . Increased neopterin concentrations are associated with rejection episodes in allograft recipients as well as with viral or bacterial infections. In patients with autoimmune disorders neopterin concentrations correlate with the extent and the activity of the disease (8 ) .
Neopterin levels were exarninated earlier in patients with different thyroid disease (20) . The majority of patients with autoimmune thyroid diseases were found to have increased serum neopterin concentration (9) . Serum neopterin levels were frequently cle-vated in patients with autoimmw1e thyrotoxicosis and with autoimmlU1e hypothyroidism but not in patients with disseminated autonomy and with goitre (21) . Neopterin levels normalized during treatment of hyperthyroid patients when thyroid hormones normalized but remained elevated when the course of disease did not change. Higher neopterin levels are due to the autoimmune response of a large amount of macrophages infIltrating the thyroid gland resulting in sufficient neopterin generation to cause an increase in the peripheral blcx)d (23) . A combination of neopterin levels and TSH-receptor stimulatory antibody titre.., was suggested as an "autoimmune activity index specific for the thyroid".
The present study shows signifIcantly elevated levels of interleukin-6 in patients with all thyroid diseases. Our results are in agreement with those described previously in patients with thyroid diseases (1) .
Autoantibodies ATG were detected in serum of 51.1 % and autoantibodies MAB were in serum of 38.6% patients. The mean levels of these autoantibodies in patients were signifIcantly higher than in normal control. In patients with ATG and/or MAB the level of neopterin was signifIcantly higher than in patients without these autoantibodies, but we didnt fInd a signifIcant correlation between the levels of neopterin and the levels of ATG and MAB. Wagner et al. (23) found a significant positive correlation between senlm neopterin levels and antithyroglobulin antibodies.
Autoantibodies directed against thyreoglobulin and thyroperoxidase are frequently detected in the serum of patients with autoimmune thyroid diseases (10 ) . The level of antibodies to the thyroid gland increase with age. Antimicrosomal antibodies are another indicator along with an elevated TSH concentration that can lead to the diagnosis of hypothyroidism ( 15, 19) .
In conclusion, the results of our study, are consistent with the concept tl1at ncopterin represents an additional parameter with potential interest in clinical diagnosis of thyroid diseases.
